Grants paid by Emerald Foundation Inc Co Solomon Blum Heymann
EIN 13-3912580 · New York, NY · Form 990-PF, Part XV · NTEE T20J
Emerald Foundation Inc Co Solomon Blum Heymann of New York, NY (EIN 13-3912580) reported 94 grants paid totaling $7,315,000 to 37 recipients in tax years 2018–2024, on Form 990-PF, Part XV. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$7,315,000
94 grants
Recipients
37
distinct organizations
Tax years
2018–2024
6 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2018 | 11 | $1,350,000 | — |
| 2020 | 10 | $1,125,000 | — |
| 2021 | 14 | $1,425,000 | — |
| 2022 | 19 | $1,190,000 | — |
| 2023 | 19 | $1,112,500 | — |
| 2024 | 21 | $1,112,500 | — |
Top recipients
The 37 recipients receiving the most from Emerald Foundation Inc Co Solomon Blum Heymann, by grants paid, out of 37 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Massachusetts Institute of Technology 04-2103594 | B | Cambridge, MA | 5 | $612,500 | 2024 |
| Salk Institute for Biological Studies 95-2160097 | B | La Jolla, CA | 8 | $575,000 | 2024 |
| Dana-Farber Cancer Institute 04-2263040 | B | Boston, MA | 6 | $450,000 | 2024 |
| Rockefeller Universtity 13-1624158 | D | New York, NY | 4 | $450,000 | 2022 |
| John Hopkins University | U | Baltimore, MD | 9 | $405,000 | 2024 |
| Ma Institute of Technology | U | Cambridge, MA | 6 | $375,000 | 2023 |
| Regents of the University of California | U | La Jolla, CA | 2 | $300,000 | 2020 |
| Brigham and Women's Hospital Inc 04-2312909 | C | Boston, MA | 2 | $300,000 | 2021 |
| University of Md Baltimore Foundati | U | Baltimore, MD | 3 | $300,000 | 2023 |
| Whitehead Institute for Biomedical Research 06-1043412 | B | Cambridge, MA | 5 | $287,500 | 2023 |
| Nyu School of Medicine | U | New York, NY | 4 | $262,500 | 2024 |
| Regents of the University of Michigan 38-6006309 | B | Ann Arbor, MI | 2 | $225,000 | 2018 |
| University of California San Francisco 94-6036493 | C | San Francisco, CA | 2 | $225,000 | 2021 |
| Georgetown University 23-7333567 | B | Washington, DC | 1 | $150,000 | 2018 |
| Uc San Diego Foundation | U | La Jolla, CA | 2 | $150,000 | 2018 |
| Weill Med College of Cornell U | U | New York, NY | 1 | $150,000 | 2022 |
| Tisch Multiple Sclerosis Research Center of New York Inc 25-1922851 | B | New York, NY | 1 | $150,000 | 2018 |
| University of Maryland Sch of Medic | U | Baltimore, MD | 2 | $150,000 | 2024 |
| Memorial Sloan-Kettering Cancer Center | U | New York, NY | 2 | $150,000 | 2021 |
| Loyola University of Chicago 36-1408475 | C | Maywood, IL | 1 | $150,000 | 2018 |
| Weill Cornell Medicine | U | New York, NY | 1 | $150,000 | 2021 |
| University of Ky | U | Lexington, KY | 2 | $137,500 | 2023 |
| Institute for Cancer Research 23-6296135 | C | Philadelphia, PA | 4 | $117,500 | 2023 |
| Ca Institute of Technology | U | Pasadena, CA | 2 | $117,500 | 2023 |
| Fox Chase Cancer Center 23-2003072 | C | Philadelphia, PA | 2 | $112,500 | 2024 |
| University of Pennsylvania | U | Philadelphia, PA | 2 | $100,000 | 2024 |
| University of Kentucky 61-1104212 | C | Lexington, KY | 2 | $100,000 | 2024 |
| University of Guelph | U | East Guelph, ONTARIO | 1 | $100,000 | 2022 |
| University of Guelph | U | Guelph, Ontario | 1 | $100,000 | 2021 |
| Hackensack University Medical Center | U | Hackensack, NJ | 1 | $75,000 | 2018 |
| Johns Hopkins University | U | Baltimore, MD | 1 | $75,000 | 2021 |
| Who We Play for Inc 46-2485938 | C | Cocoa Beach, FL | 2 | $75,000 | 2024 |
| University of Chicago | U | Chicago, IL | 1 | $75,000 | 2020 |
| University of Michigan | U | Ann Arbor, MI | 1 | $50,000 | 2024 |
| University of Ca Santa Barbara 31-0964066 | B | Santa Barbara, CA | 1 | $37,500 | 2022 |
| Harvard Medical School | U | Boston, MD | 1 | $37,500 | 2024 |
| Harvard Medical School 04-2213292 | D | Boston, MA | 1 | $37,500 | 2024 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 94 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Massachusetts Institute of Technolo Cambridge, MA | C | $87,500 | paid | To study how ferroptosis-based strategies can enhance the efficacy of immunotherapies in breast cancer. | 202522949349100217 |
| 2024 | University of Maryland Sch of Medic Baltimore, MD | U | $75,000 | paid | TO INVESTIGATE THE REGULATION OF TREG LYMPHATIC TUMOR MIGRATION AND THE INTERACTION AMONG TREGS, LYMPHATIC ENDOTHELIAL CELLS, AND TUMORS TO DEVELOP STRATEGIES OF DELIVERING TARGETED THERAPIES LOCALLY INSTEAD OF SYSTEMICALLY. | 202522949349100217 |
| 2024 | Nyu School of Medicine New York, NY | U | $75,000 | paid | To examine the cellular mechanisms through which dendrite-centric Alzheimer's disease pathologies result in cognitive dysfunction and hyper-excitability. | 202522949349100217 |
| 2024 | University of Maryland Sch of Medic Baltimore, MD | U | $75,000 | paid | To investigate the regulation of Treg lymphatic tumor migration and the interaction among Tregs, lymphatic endothelial cells, and tumors to develop strategies of delivering targeted therapies locally instead of systemically. | 202522949349100217 |
| 2024 | Massachusetts Institute of Technolo Cambridge, MA | C | $75,000 | paid | To enhance nanoparticle accumulation in desired cell types to develop more effective and safer targeted nanotherapies. | 202522949349100217 |
| 2024 | Dana-Farber Cancer Institute Boston, MA | B | $50,000 | paid | To map the transcriptional and protein changes induced by lactate and identify the mechanisms that cause NK suppression, on both NK and tumor cells, using high-throughput and unbiased approaches. | 202522949349100217 |
| 2024 | University of Pennsylvania Philadelphia, PA | U | $50,000 | paid | To understand the molecular mechanism underlying immunosuppression and immunoactivation and develop new treatment strategies for hepatic malignancies. | 202522949349100217 |
| 2024 | Salk Institute for Bio Studies La Jolla, CA | C | $50,000 | paid | To use innovative cell biology techniques coupled with genomics to investigate the role of mitochondrial-derived vesicles in cancer cell metabolism. | 202522949349100217 |
| 2024 | Salk Institute for Biological Studi La Jolla, CA | C | $50,000 | paid | TO USE INNOVATIVE CELL BIOLOGY TECHNIQUES COUPLED WITH GENOMICS TO INVESTIGATE THE ROLE OF MITOCHONDRIAL-DERIVED VESICLES IN CANCER CELL METABOLISM. | 202522949349100217 |
| 2024 | University of Kentucky Lexington, KY | C | $50,000 | paid | To understand how maladaptive changes to the integrated stress response pathway alter the force generating ability of human heart cells and determine if pharmacological manipulation can rescue cardiomyocyte function. | 202522949349100217 |
| 2024 | Dana-Farber Cancer Institute Boston, MA | B | $50,000 | paid | To map the transcriptional and protein changes induced by lactate and identify the mechanisms that cause NK suppression, on both NK and tumor cells, using high-throughput and unbiased approaches. | 202522949349100217 |
| 2024 | John Hopkins University Baltimore, MD | U | $50,000 | paid | To investigate how the colon microbiota and host genetics intersect to alter responsiveness to immunotherapy in colorectal cancer. | 202522949349100217 |
| 2024 | University of Kentucky Lexington, KY | C | $50,000 | paid | TO UNDERSTAND HOW MALADAPTIVE CHANGES TO THE INTEGRATED STRESS RESPONSE PATHWAY ALTER THE FORCE GENERATING ABILITY OF HUMAN HEART CELLS AND DETERMINE IF PHARMACOLOGICAL MANIPULATION CAN RESCUE CARDIOMYOCYTE FUNCTION. | 202522949349100217 |
| 2024 | University of Michigan Ann Arbor, MI | U | $50,000 | paid | To use tumor organoid and mouse models to determine how loss of Claudin proteins impacts tumor invasion and metastasis. | 202522949349100217 |
| 2024 | University of Pennsylvania Philadelphia, PA | U | $50,000 | paid | To understand the molecular mechanism underlying immunosuppression and immunoactivation and develop new treatment strategies for hepatic malignancies. | 202522949349100217 |
| 2024 | Who We Play for Inc Cocoa Beach, FL | C | $37,500 | paid | To screen young students for previously undiagnosed heart ailments and generate data that can be used to train AI programs to better evaluate electrocardiograms. | 202522949349100217 |
| 2024 | Fox Chase Cancer Center Philadelphia, PA | C | $37,500 | paid | To investigate the role of Brg1-dependent epigenetic regulation on PDAC fibroblast pro-tumorigenic functions. | 202522949349100217 |
| 2024 | Harvard Medical School Boston, MD | U | $37,500 | paid | To study how SLC7A5 regulates metabolic reprogramming and signaling pathways that enable cancer cells to survive CDK4/6i treatment. | 202522949349100217 |
| 2024 | Nyu School of Medicine New York, NY | U | $37,500 | paid | To characterize interactions between proteins that associate only with the KRAS4A isoform to identifying pathways that can be rationally targeted to achieve a more comprehensive interruption of KRAS stimulation. | 202522949349100217 |
| 2024 | John Hopkins University Baltimore, MD | U | $37,500 | paid | To use tumor organoid and mouse models to determine how loss of claudin proteins impacts tumor invasion and metastasis. | 202522949349100217 |
| 2024 | Harvard Medical School Boston, MA | D | $37,500 | paid | To study how SLC7A5 regulates metabolic reprogramming and signaling pathways that enable cancer cells to survive CDK4/6i treatment. | 202522949349100217 |
| 2023 | University of Md Baltimore Foundati Baltimore, MD | U | $150,000 | paid | TO INVESTIGATE THE REGULATION OF TREG LYMPHATIC TUMOR MIGRATION AND THE INTERACTION AMONG TREGS, LYMPHATIC ENDOTHELIAL CELLS, AND TUMORS TO DEVELOP STRATEGIES OF DELIVERING TARGETED THERAPIES LOCALLY INSTEAD OF SYSTEMICALLY. | 202432829349100803 |
| 2023 | University of Ky Lexington, KY | U | $100,000 | paid | TO UNDERSTAND HOW MALADAPTIVE CHANGES TO THE INTEGRATED STRESS RESPONSE PATHWAY ALTER THE FORCE GENERATING ABILITY OF HUMAN HEART CELLS AND DETERMINE IF PHARMACOLOGICAL MANIPULATION CAN RESCUE CARDIOMYOCYTE FUNCTION. | 202432829349100803 |
| 2023 | John Hopkins University Baltimore, MD | U | $100,000 | paid | TO INVESTIGATE HOW THE COLON MICROBIOTA AND HOST GENETICS INTERSECT TO ALTER RESPONSIVENESS TO IMMUNOTHERAPY IN COLORECTAL CANCER. | 202432829349100803 |
| 2023 | Dana-Farber Cancer Institute Boston, MA | B | $100,000 | paid | TO MAP THE TRANSCRIPTIONAL AND PROTEIN CHANGES INDUCED BY LACTATE AND IDENTIFY THE MECHANISMS THAT CAUSE NK SUPPRESSION, ON BOTH NK AND TUMOR CELLS, USING HIGH-THROUGHPUT AND UNBIASED APPROACHES. | 202432829349100803 |
| 2023 | Ma Institute of Technology Cambridge, MA | U | $75,000 | paid | TO ENHANCE NANOPARTICLE ACCUMULATION IN DESIRED CELL TYPES TO DEVELOP MORE EFFECTIVE AND SAFER TARGETED NANOTHERAPIES. | 202432829349100803 |
| 2023 | John Hopkins University Baltimore, MD | U | $50,000 | paid | TO INVESTIGATE HOW THE COLON MICROBIOTA AND HOST GENETICS INTERSECT TO ALTER RESPONSIVENESS TO IMMUNOTHERAPY IN COLORECTAL CANCER. | 202432829349100803 |
| 2023 | Salk Institute for Bio Studies La Jolla, CA | C | $50,000 | paid | TO USE INNOVATIVE CELL BIOLOGY TECHNIQUES COUPLED WITH GENOMICS TO INVESTIGATE THE ROLE OF MITOCHONDRIAL-DERIVED VESICLES IN CANCER CELL METABOLISM. | 202432829349100803 |
| 2023 | Whitehead Institute for Biomed Cambridge, MA | D | $50,000 | paid | TO UNCOVER THE SET OF CELL-SURFACE PROTEINS THAT MEDIATE ESSENTIAL INTERACTIONS BETWEEN PDAC CELLS AND THEIR MICROENVIRONMENT. | 202432829349100803 |
| 2023 | Whitehead Institute for Biomed Cambridge, MA | D | $50,000 | paid | TO UNCOVER THE SET OF CELL-SURFACE PROTEINS THAT MEDIATE ESSENTIAL INTERACTIONS BETWEEN PDAC CELLS AND THEIR MICROENVIRONMENT. | 202432829349100803 |
| 2023 | Salk Institute for Bio Studies La Jolla, CA | C | $50,000 | paid | TO USE INNOVATIVE CELL BIOLOGY TECHNIQUES COUPLED WITH GENOMICS TO INVESTIGATE THE ROLE OF MITOCHONDRIAL-DERIVED VESICLES IN CANCER CELL METABOLISM. | 202432829349100803 |
| 2023 | Institute for Cancer Research Philadelphia, PA | C | $37,500 | paid | TO INVESTIGATE THE ROLE OF BRG1-DEPENDENT EPIGENETIC REGULATION ON PDAC FIBROBLAST PRO-TUMORIGENIC FUNCTIONS. | 202432829349100803 |
| 2023 | Who We Play for Inc Cocoa Beach, FL | C | $37,500 | paid | TO SCREEN YOUNG STUDENTS FOR PREVIOUSLY UNDIAGNOSED HEART AILMENTS AND GENERATE DATA THAT CAN BE USED TO TRAIN AI PROGRAMS TO BETTER EVALUATE ELECTROCARDIOGRAMS. | 202432829349100803 |
| 2023 | John Hopkins University Baltimore, MD | U | $37,500 | paid | TO USE TUMOR ORGANOID AND MOUSE MODELS TO DETERMINE HOW LOSS OF CLAUDIN PROTEINS IMPACTS TUMOR INVASION AND METASTASIS. | 202432829349100803 |
| 2023 | John Hopkins University Baltimore, MD | U | $37,500 | paid | TO USE TUMOR ORGANOID AND MOUSE MODELS TO DETERMINE HOW LOSS OF CLAUDIN PROTEINS IMPACTS TUMOR INVASION AND METASTASIS. | 202432829349100803 |
| 2023 | Ca Institute of Technology Pasadena, CA | U | $37,500 | paid | TO DEVELOP INTERPRETABLE MACHINE LEARNING METHODS THAT LINK SPATIAL PHENOTYPES IN IMAGING DATA OF SOLID TUMORS WITH PATIENT OUTCOMES. | 202432829349100803 |
| 2023 | Ma Institute of Technology Cambridge, MA | U | $37,500 | paid | TO DEVELOP A HIGH-THROUGHPUT SINGLE-CELL GRO-SEQ ASSAY TO EXAMINE THE TUMOR MICROENVIRONMENT ESTABLISHED BY MUTANT-P53 AND DECIPHER THE GENE REGULATORY NETWORKS UNDERLYING PDAC'S INTRANSIGENCE TO IMMUNOTHERAPIES. | 202432829349100803 |
| 2023 | Whitehead Institute for Biomed Cambridge, MA | D | $37,500 | paid | TO STUDY HOW FERROPTOSIS-BASED STRATEGIES CAN ENHANCE THE EFFICACY OF IMMUNOTHERAPIES IN BREAST CANCER. | 202432829349100803 |
| 2023 | Ma Institute of Technology Cambridge, MA | U | $37,500 | paid | TO DEVELOP A HIGH-THROUGHPUT SINGLE-CELL GRO-SEQ ASSAY TO EXAMINE THE TUMOR MICROENVIRONMENT ESTABLISHED BY MUTANT-P53 AND DECIPHER THE GENE REGULATORY NETWORKS UNDERLYING PDAC'S INTRASIGENCE TO IMMUNOTHERAPIES. | 202432829349100803 |
| 2023 | Institute for Cancer Research Philadelphia, PA | C | $37,500 | paid | TO INVESTIGATE THE ROLE OF BRG1-DEPENDENT EPIGENETIC REGULATION ON PDAC FIBROBLAST PRO-TUMORIGENIC FUNCTIONS. | 202432829349100803 |
| 2022 | Weill Med College of Cornell U New York, NY | U | $150,000 | paid | TO IDENTIFY REGULATORS OF LINEAGE REVERSION THAT IMPACT RESISTANCE TO WNT-TARGETED THERAPIES IN COLORECTAL CANCER. | 202303209349101450 |
| 2022 | Ma Institute of Technology Cambridge, MA | U | $150,000 | paid | TO ENHANCE NANOPARTICLE ACCUMULATION IN DESIRED CELL TYPES TO DEVELOP MORE EFFECTIVE AND SAFER TARGETED NANOTHERAPIES. | 202303209349101450 |
| 2022 | Dana-Farber Cancer Institute Boston, MA | B | $100,000 | paid | TO MAP THE TRANSCRIPTIONAL AND PROTEIN CHANGES INDUCED BY LACTATE AND IDENTIFY THE MECHANISMS THAT CAUSE NK SUPPRESSION, ON BOTH NK AND TUMOR CELLS, USING HIGH-THROUGHPUT AND UNBIASED APPROACHES. | 202303209349101450 |
| 2022 | University of Guelph East Guelph, ONTARIO | U | $100,000 | paid | TO IDENTIFY COMBINATIONS OF COMMERCIAL BACTERIAL ISOLATES THAT SUPPRESS KLEBSIELLA PNEUMONIAE IN THE COLON AND THE UNDERLYING COOPERATIVE MECHANISMS OF THIS ACTIVITY. | 202303209349101450 |
| 2022 | Ca Institute of Technology Pasadena, CA | U | $80,000 | paid | TO DEVELOP INTERPRETABLE MACHINE LEARNING METHODS THAT LINK SPATIAL PHENOTYPES IN IMAGING DATA OF SOLID TUMORS WITH PATIENT OUTCOMES. | 202303209349101450 |
| 2022 | University of Md Baltimore Foundati Baltimore, MD | U | $75,000 | paid | TO INVESTIGATE THE REGULATION OF TREG LYMPHATIC TUMOR MIGRATION AND THE INTERACTION AMONG TREGS, LYMPHATIC ENDOTHELIAL CELLS, AND TUMORS TO DEVELOP STRATEGIES OF DELIVERING TARGETED THERAPIES LOCALLY INSTEAD OF SYSTEMICALLY. | 202303209349101450 |
| 2022 | Rockefeller University New York, NY | B | $75,000 | paid | TO INVESTIGATE THE ROLE OF TRNA-DERIVED FRAGMENTS AND THE GENES THEY REGULATE IN BREAST CANCER PROGRESSION AND METASTASIS. | 202303209349101450 |
| 2022 | University of Md Baltimore Foundati Baltimore, MD | U | $75,000 | paid | TO INVESTIGATE THE REGULATION OF TREG LYMPHATIC TUMOR MIGRATION AND THE INTERACTION AMONG TREGS, LYMPHATIC ENDOTHELIAL CELLS, AND TUMORS TO DEVELOP STRATEGIES OF DELIVERING TARGETED THERAPIES LOCALLY INSTEAD OF SYSTEMICALLY. | 202303209349101450 |
| 2022 | Whitehead Institute for Biomed Cambridge, MA | D | $50,000 | paid | TO UNCOVER THE SET OF CELL-SURFACE PROTEINS THAT MEDIATE ESSENTIAL INTERACTIONS BETWEEN PDAC CELLS AND THEIR MICROENVIRONMENT. | 202303209349101450 |
| 2022 | John Hopkins University Baltimore, MD | U | $50,000 | paid | TO INVESTIGATE HOW THE COLON MICROBIOTA AND HOST GENETICS INTERSECT TO ALTER RESPONSIVENESS TO IMMUNOTHERAPY IN COLORECTAL CANCER. | 202303209349101450 |
| 2022 | Salk Institute for Bio Studies La Jolla, CA | C | $50,000 | paid | TO USE INNOVATIVE CELL BIOLOGY TECHNIQUES COUPLED WITH GENOMICS TO INVESTIGATE THE ROLE OF MITOCHONDRIAL-DERIVED VESICLES IN CANCER CELL METABOLISM. | 202303209349101450 |
| 2022 | Ma Institute of Technology Cambridge, MA | U | $37,500 | paid | TO DEVELOP A HIGH-THROUGHPUT SINGLE-CELL GRO-SEQ ASSAY TO EXAMINE THE TUMOR MICROENVIRONMENT ESTABLISHED BY MUTANT-P53 AND DECIPHER THE GENE REGULATORY NETWORKS UNDERLYING PDAC'S INTRASIGENCE TO IMMUNOTHERAPIES. | 202303209349101450 |
| 2022 | Institute for Cancer Research Philadelphia, PA | C | $37,500 | paid | TO INVESTIGATE THE ROLE OF BRG1-DEPENDENT EPIGENETIC REGULATION ON PDAC FIBROBLAST PRO-TUMORIGENIC FUNCTIONS. | 202303209349101450 |
| 2022 | Ma Institute of Technology Cambridge, MA | U | $37,500 | paid | TO DEVELOP A HIGH-THROUGHPUT SINGLE-CELL GRO-SEQ ASSAY TO EXAMINE THE TUMOR MICROENVIRONMENT ESTABLISHED BY MUTANT-P53 AND DECIPHER THE GENE REGULATORY NETWORKS UNDERLYING PDAC'S INTRANSIGENCE TO IMMUNOTHERAPIES. | 202303209349101450 |
| 2022 | University of Ky Lexington, KY | U | $37,500 | paid | TO UNDERSTAND HOW MALADAPTIVE CHANGES TO THE INTEGRATED STRESS RESPONSE PATHWAY ALTER THE FORCE GENERATING ABILITY OF HUMAN HEART CELLS AND DETERMINE IF PHARMACOLOGICAL MANIPULATION CAN RESCUE CARDIOMYOCYTE FUNCTION. | 202303209349101450 |
| 2022 | John Hopkins University Baltimore, MD | U | $37,500 | paid | TO USE TUMOR ORGANOID AND MOUSE MODELS TO DETERMINE HOW LOSS OF CLAUDIN PROTEINS IMPACTS TUMOR INVASION AND METASTASIS. | 202303209349101450 |
| 2022 | University of Ca Santa Barbara Santa Barbara, CA | B | $37,500 | paid | TO UNDERSTAND HOW MALADAPTIVE CHANGES TO THE INTEGRATED STRESS RESPONSE PATHWAY ALTER THE FORCE GENERATING ABILITY OF HUMAN HEART CELLS AND DETERMINE IF PHARMACOLOGICAL MANIPULATION CAN RESCUE CARDIOMYOCYTE FUNCTION. | 202303209349101450 |
| 2022 | Institute for Cancer Research Philadelphia, PA | C | $5,000 | paid | TO INVESTIGATE THE ROLE OF BRG1-DEPENDENT EPIGENETIC REGULATION ON PDAC FIBROBLAST PRO-TUMORIGENIC FUNCTIONS. | 202303209349101450 |
| 2022 | John Hopkins University Baltimore, MD | U | $5,000 | paid | TO INVESTIGATE HOW THE COLON MICROBIOTA AND HOST GENETICS INTERSECT TO ALTER RESPONSIVENESS TO IMMUNOTHERAPY IN COLORECTAL CANCER. | 202303209349101450 |
| 2021 | Brigham and Women's Hospital Inc Boston, MA | C | $150,000 | paid | To uncover and validate druggable targets that can be combined with MEK/ERK inhibitors to treat RAS pathway-driven malignancies, especially melanoma. | 202202239349100625 |
| 2021 | Massachusetts Institute of Technology Cambridge, MA | B | $150,000 | paid | To investigate the role of diet and nutrient availability in tumor growth, progression, and response to treatment. | 202202239349100625 |
| 2021 | Weill Cornell Medicine New York, NY | U | $150,000 | paid | To identify regulators of lineage reversion that impact resistance to WNT-targeted therapies in colorectal cancer. | 202202239349100625 |
| 2021 | Massachusetts Institute of Technology Cambridge, MA | B | $150,000 | paid | To engance nanoparticle accumulation in desired cell types to develop more effective and safer targeted nanotherapies. | 202202239349100625 |
| 2021 | Whitehead Institute for Biomedical Research Cambridge, MA | B | $100,000 | paid | To investigate the role of tRNA-derived fragments and the genes they regulate in breast cancer progression and metastasis. | 202202239349100625 |
| 2021 | Salk Institute for Biological Studies La Jolla, CA | B | $100,000 | paid | To investigate the potential of CA19-9 as a therapeutic target for pancreatic cancer treatment and to discover pharmacological approaches to blocking CA19-9 production in malignant cells. | 202202239349100625 |
| 2021 | University of Guelph Guelph, Ontario | U | $100,000 | paid | To identify combinations of commercial bacterial isolates that suppress Klebsiella pneumoniae in the colon and the underlying cooperative mechanisms of this activity. | 202202239349100625 |
| 2021 | Dana-Farber Cancer Institute Boston, MA | B | $75,000 | paid | To optimize USP8 inhibitors and test their activity in models of neurodegenerative disease, non-small cell lung cancer, and other applicable systems. | 202202239349100625 |
| 2021 | Johns Hopkins University Baltimore, MD | U | $75,000 | paid | To investigate how the colon microbiota and host genetics intersect to alter responsiveness to immunotherapy in colorectal cancer. | 202202239349100625 |
| 2021 | Memorial Sloan-Kettering Cancer Center New York, NY | U | $75,000 | paid | To investigate the molecular mechanisms underlying how endgogenous DNA-modifying enzymes lead to cancer genome evolution. | 202202239349100625 |
| 2021 | University of California San Francisco San Francisco, CA | C | $75,000 | paid | To develop a small molecule that stabilizes mutant P53 in cancer and further elaborate this compound with the ability to increase DNA binding of bound P53. | 202202239349100625 |
| 2021 | Nyu School of Medicine New York, NY | U | $75,000 | paid | To investigate how metabolic rewiring in distinct genetic subtypes of lung cancer impacts immune cell infiltration and leads to immune evasion. | 202202239349100625 |
| 2021 | Rockefeller Universtity New York, NY | D | $75,000 | paid | To investigate the role of tRNA-derived fragments and the genes they regulate in breast cancer progression and metastasis. | 202202239349100625 |
| 2021 | Fox Chase Cancer Center Philadelphia, PA | C | $75,000 | paid | To investigate the role of Brg1-depedent epigenetic regulation on PDAC fibroblast pro-tumorigenic functions. | 202202239349100625 |
| 2020 | Regents of the University of California La Jolla, CA | U | $150,000 | paid | To (1) define a microbiome growth curce in healthy children, (2) determine when and why deviation from this curve occurs, and (3) investigate known, as well as discover new, microbiome-linked disorders and relationships among them, and analyze microbiome associations with clinical presentations of COVID-19. | 202112879349101111 |
| 2020 | Rockefeller University New York, NY | B | $150,000 | paid | To investigate the role of tRNA-derived fragments and the genes they regulate in breast cancer progression and metastasis. | 202112879349101111 |
| 2020 | Brigham and Women's Hospital Inc Boston, MA | C | $150,000 | paid | To uncover and validate druggable targets that can be combined with MEK/ERK inhibitors to treat RAS pathway-driven malignancies, especially melanoma. | 202112879349101111 |
| 2020 | Massachusetts Institute of Technology Cambridge, MA | B | $150,000 | paid | To investigate the role of diet and nutrient availability in tumor growth, progression, and response to treatment. | 202112879349101111 |
| 2020 | University of California San Francisco San Francisco, CA | C | $150,000 | paid | To develop a small molecule that stabilizes mutant P53 in cancer and further elaborate this compound with the ability to increase DNA binding of bound P53. | 202112879349101111 |
| 2020 | Memorial Sloan-Kettering Cancer Center New York, NY | U | $75,000 | paid | To investigate the molecular mechanisms underlying how endgogenous DNA-modifying enzymes lead to cancer genome evolution. | 202112879349101111 |
| 2020 | Nyu School of Medicine New York, NY | U | $75,000 | paid | To investigate how metabolic rewiring in distinct genetic subtypes of lung cancer impacts immune cell infiltration and leads to immune evasion. | 202112879349101111 |
| 2020 | Salk Institute for Biological Studies La Jolla, CA | B | $75,000 | paid | To investigate the potential of CA19-9 as a therapeutic target for pancreatic cancer treatment and to discover pharmacological approaches to blocking CA19-9 production in malignant cells. | 202112879349101111 |
| 2020 | University of Chicago Chicago, IL | U | $75,000 | paid | To identify combinations of commensal bacterial isolates that suppress Klebsiella pneumoniae in the colon and the underlying cooperative mechanisms of this activity. | 202112879349101111 |
| 2020 | Dana-Farber Cancer Institute Boston, MA | B | $75,000 | paid | To optimize USP8 inhibitors and test their activity in models of neurodegenerative disease, non-small cell lung cancer, and other applicable systems. | 202112879349101111 |
| 2018 | Salk Institute for Biological Studies La Jolla, CA | B | $150,000 | paid | To analyze the potential therapeutic effect of blocking fatty acid synthesis in non-small cell lung cancer through the use of novel enzymatic inhibitors. | 201901229349101720 |
| 2018 | Georgetown University Washington, DC | B | $150,000 | paid | To investigate how USP-13, a protein involved in the clearance of misfolded and abnormal proteins, may function as a regulator to clear proteins implicated in the development and progression of neurodegenerative diseases. | 201901229349101720 |
| 2018 | Regents of the University of California La Jolla, CA | U | $150,000 | paid | To (1) define a microbiome growth curce in healthy children, (2) determine when and why deviation from this curve occurs, and (3) investigate known, as well as discover new, microbiome-linked disorders and relationships among them. | 201901229349101720 |
| 2018 | Regents of the University of Michigan Ann Arbor, MI | B | $150,000 | paid | To develop a novel cancer vaccine using artificial virus-like particles, and to analyze its efficacy in the development of anti-tumor clearance, and long-term immunity. | 201901229349101720 |
| 2018 | Loyola University of Chicago Maywood, IL | C | $150,000 | paid | To investigate how the transfer of alpha-synuclein between cells in the nervous system induces neuroinflammation that drives Parkinson's Disease pathogenesis. | 201901229349101720 |
| 2018 | Rockefeller University New York, NY | B | $150,000 | paid | To determine the role of BRCA2 and other DNA repair proteins, which are important for neural progenitor cells of the cerebellem, in the development of medulloblastoma, the most common pediatric brain malignancy. | 201901229349101720 |
| 2018 | Tisch Multiple Sclerosis Research Center of New York Inc New York, NY | B | $150,000 | paid | To elucidate the cause of MS by investigating 3 synergistic factors: 1) the initial trigger that generates the anitbody response in MS; 2) the role of Epstein - Barr virus in the development of autoimmunity in MS; and 3) the role of anti-myelin antibodies in sustaining the ongoing demyelination and disease. | 201901229349101720 |
| 2018 | Uc San Diego Foundation La Jolla, CA | U | $75,000 | paid | To examine how the downregulation of EdnrB, a gene found to be selective' in the high altitude human population, can preserve cardiovascular function during acute hyposia. | 201901229349101720 |
| 2018 | Hackensack University Medical Center Hackensack, NJ | U | $75,000 | paid | To evaluate potential therapies to decrease cell adhesion interaction-mediated drug resistance in multiple myeloma, a type of hematological cancer characterized by the uncontrollable proliferation of plasma immune cells in the bone marrow. | 201901229349101720 |
| 2018 | Uc San Diego Foundation La Jolla, CA | U | $75,000 | paid | To analyze sequencing data from subjects living in high altitude conditions in Kyrgystan with or without high altitude pulmonary hypertension, in order to select and screen candidate genes for the development of pulmonary hypertension. | 201901229349101720 |
| 2018 | Regents of the University of Michigan Ann Arbor, MI | B | $75,000 | paid | To study the role of a protein modification process known as AMPylation on heat shock protein function in the onset, development, and progression of neurodegenerative diseases (Alzheimer's, Parkinson's, and Huntington diseases) | 201901229349101720 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990PF | 2024 | 2024-12-31 | not stated | 2024v5.2 | 202522949349100217 |
| 990PF | 2023 | 2023-12-31 | not stated | 2023v5.1 | 202432829349100803 |
| 990PF | 2022 | 2022-12-31 | not stated | 2022v5.0 | 202303209349101450 |
| 990PF | 2021 | 2021-12-31 | not stated | 2021v4.2 | 202202239349100625 |
| 990PF | 2020 | 2020-12-31 | not stated | 2020v4.1 | 202112879349101111 |
| 990PF | 2018 | 2018-12-31 | not stated | 2018v3.1 | 201901229349101720 |
Derived from IRS Form 990-PF e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/133912580.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.